Medical/Pharmaceuticals
Strategic Partnership Between Sanyou Bio and Yugong Bio to Accelerate Expansion in High-End Synthetic Enzyme Market
SHANGHAI, Nov. 11, 2025 /PRNewswire/ -- Sanyou Bio and Yugong Bio today announced the signing of a strategic cooperation agreement. This powerful alliance marks a significant step to deepen their collaboration in the development of high-end synthetic molecular enzymes. This collaboration is base...
2025-11-11 22:00
1038
The Sigourney Award-2025 Celebrates Four Recipients Honored for Creative Trailblazing Work Expanding Psychoanalytic Thought Globally
Interdisciplinary Work from Israel, Uruguay, and the United States Earns The Prestigious Sigourney Award-2025 Prize SAN FRANCISCO, Nov. 11, 2025 /PRNewswire/ -- The trailblazing work of four recipients has won The Sigourney Award-2025, earning international recognition and a substantial cash pri...
2025-11-11 21:11
960
SOPHiA GENETICS and Element Biosciences Unite Sequencing Power and AI Analytics to Accelerate Global Research In Precision Medicine
BOSTON and SAN DIEGO, Nov. 11, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and Element Biosciences, Inc., a biology company transforming the pace and accessibility of scientific discovery, today announced at theAssociation for Molecular Pa...
2025-11-11 21:01
849
Coreline Soft Selected as Exclusive AI Provider for France's National Lung Cancer Screening Pilot Project, IMPULSION
- APHP-led IMPULSION project secures Coreline Soft as sole AI supplier
- UGAP (France's central public procurement agency) registration completed,
opening opportunities withFrance's largest public hospitals
SEOUL, South Korea, Nov. 11, 2025 /PRNewswire/ -- Coreline Soft
2025-11-11 21:00
913
Waters Boosts Lab Productivity and Sample Throughput with Launch of its Charged Aerosol Detector Designed for Empower Software
* Drives efficiency and reliability in Quality Control and Development environments, integrating seamlessly with world-class Empower™ Chromatography Data System (CDS). * Mitigates CDS communication errors encountered in up to 70% of multi-vendor LC-CAD configurations.1 * Delivers near-unive...
2025-11-11 21:00
976
MGI Tech Joins Forces with SAMRC and DSTI to Launch South Africa's 110K Human Genome Program and Unveil Africa's First DNBSEQ-T7, Ushering a New Era in African Genomics
CAPE TOWN, South Africa, Nov. 11, 2025 /PRNewswire/ -- MGI Tech Co., Ltd., a company dedicated to developing core tools and technologies that drive innovation in life sciences, today announced two historic milestones in African genomics: the official unveiling of the continent's first DNBSEQ-T7 s...
2025-11-11 17:40
1008
Apollo Cancer Centres Turns Chocolates into Health Reminders with 'Check-Olate'
NEW DELHI, Nov. 11, 2025 /PRNewswire/ -- To observe this year's Breast Cancer Awareness Month, Apollo Cancer Centres (ACCs) recently launched acrossIndia a unique initiative that blended indulgence with awareness through'Check-Olate', a sweet treat that carries an even sweeter reminder: take a mo...
2025-11-11 17:15
963
Guo Guangchang: Fosun Strengthens Globalization Capabilities, Accelerates Innovation through Open Cooperation
HONG KONG, Nov. 11, 2025 /PRNewswire/ -- On 8 November, Guo Guangchang, Chairman of Fosun International, attended the 3rd Pujiang Biopharmaceutical Original Innovation Conference 2025. During the conference, Guo Guangchang stated, "At this crucial juncture today,China's pharmaceutical innovation ...
2025-11-11 15:41
2008
OMNIBOT Showcases How Connectivity Expands Possibilities in Live Telesurgery at Chilean Urology Congress
-The live telesurgery took place during the XLVI Annual Congress of the Chilean Society of Urology, which also marked the Society's 100th anniversary. This procedure highlights how network connectivity is enabling new forms of surgical collaboration. SINGAPORE, Nov. 11, 2025 /PRNewswire/ -- Duri...
2025-11-11 13:00
1177
Shilpa Pharma Lifesciences Awarded EcoVadis Gold Medal for Outstanding Sustainability Practices
RAICHUR, India, Nov. 11, 2025 /PRNewswire/ -- Shilpa Pharma Lifesciences Limited, a material subsidiary of Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), has been awarded the prestigiousGold Medal by EcoVadis, the world's most trusted provider of business sustainability ratings. The com...
2025-11-11 09:15
949
Shilpa Medicare Announces Positive Phase 3 Results for OERIS™ -- A Novel Once-Weekly Ondansetron Extended-Release Injection for Chemotherapy-Induced Nausea and Vomiting (CINV)
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections RAICHUR, India, Nov. 11, 2025 /PRNewswire/ -- Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED) announced the successfu...
2025-11-11 09:00
955
Vexev's VxWave System Successfully Meets Clinical Endpoints in Landmark Study Evaluating Robotic Ultrasound Scanning for Mapping Vascular Access at U.S. Renal Care Dialysis Clinics
* VxWave Ultrasound Imaging System demonstrated 94% scanning success rate and 100% data adequacy rate for vascular access creation strategies in CANSCAN trial * New insights into vascular anatomy made possible by standardized image acquisition and reporting * VxWave System has the potential t...
2025-11-11 05:32
1219
TraceLink Customers Demonstrate Readiness as DSCSA Dispenser Deadline Arrives
TraceLink Continues to Set the Standard for United States Drug Supply Chain Security (DSCSA) Leadership, Proven by Real-World Success, Industry Adoption, and Superior Service BOSTON, Nov. 10, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestr...
2025-11-10 23:00
1094
Brii Biosciences Presents Late-Breaking Data from Ongoing Phase 2 ENSURE Study at AASLD 2025, Reinforcing BRII-179's Potential as a Curative Treatment for Chronic Hepatitis B
* Cohort 4 follow-up confirms durable hepatitis B surface antigen (HBsAg) loss at 24 weeks post end of treatment (EOT) in BRII-179 anti-HBs responders treated with elebsiran plus pegylated interferon alfa (PEG-IFNα) * Data suggest the potential to shorten PEG-IFNα treatment duration for BRII-...
2025-11-10 21:30
2090
Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting
- Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and sustained hematologic responses – - A novel mechanism targeting NEK7 and NLRP3 inflammasomes shows promise across multiple myeloid neoplasms – - Preclinical data reveal potential applications in hemolyti...
2025-11-10 21:15
1089
Tiumbio to Present First Clinical Data for Dual TGF-β/VEGF Inhibitor Tosposertib (TU2218) at SITC 2025, "Robust Response Rate"
* 70.6% Partial Response and 82.4% Disease Control Rate Observed in Interim Phase II Data SEONGNAM, South Korea, Nov. 10, 2025 /PRNewswire/ -- On Friday, 7 November (local time) at the Society for Immunotherapy of Cancer (SITC) 2025 annual meeting, Tiumbio Co., Ltd. (KOSDAQ: 321550), a clinical...
2025-11-10 21:00
1303
Fapon to Showcase Innovative Molecular Diagnostic Solutions at AMP 2025 Annual Meeting & Expo
BOSTON, Nov. 10, 2025 /PRNewswire/ -- Fapon, a globally leading life sciences organization, will exhibit at the AMP 2025 Annual Meeting & Expo duringNovember 11-15 in Boston, presenting its cutting-edge enzymes for molecular diagnostics that power qPCR/RT-qPCR, Isothermal Amplification, and Next-...
2025-11-10 20:30
977
Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage
NANJING, China, Nov. 10, 2025 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells（Treg）-preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278, has officially entered a Phase II clinical study inChina for the treatment of moderate-to-severe atopi...
2025-11-10 20:06
1096
LISCure Biosciences Initiates Global Phase 2 Trial of LB-P8 in Primary Sclerosing Cholangitis (PSC)
SEOUL, South Korea, Nov. 10, 2025 /PRNewswire/ -- LISCure Biosciences
2025-11-10 20:00
870
Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer
HONG KONG, Nov. 10, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vaccine AK154. This trial is investigating AK154 both as a monotherapy and as a combination with the com...
2025-11-10 19:39
871
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
BeLive Studios, NewUnivers and ChopChop Systems Sign Memorandum of Understanding at ATF 2025
[Picked up by 288 media titles]
2025-12-08 11:00
2025 Guangzhou Design Week Opens: PHOMI Holdings Leads Tech Innovation in Architectural Aesthetics
[Picked up by 287 media titles]
2025-12-06 10:37
Most Read
Abu Dhabi signs agreements and explores opportunities to strengthen partnerships with India and Singapore
2025-12-06 09:00
4894
MALAYSIA REMAINS COMMITTED TO ACCELERATE TRANSFORMATIVE SOLUTIONS FOR A SUSTAINABLE AND INCLUSIVE FUTURE
2025-12-06 00:41
3985
Taipei City's Global Pass: A New Partner Channel for Global Startup Spaces
2025-12-06 01:06
3893
Dreame Technology Recognized on Fast Company's List of Brands That Matter
2025-12-06 01:30
3390
Cyient Semiconductors Qualifies for Key Bid in Semi-Conductor Laboratory-Mohali Revamp
2025-12-06 02:00
2660